<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451396</url>
  </required_header>
  <id_info>
    <org_study_id>5720</org_study_id>
    <nct_id>NCT03451396</nct_id>
  </id_info>
  <brief_title>Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms</brief_title>
  <acronym>Lifitegrast</acronym>
  <official_title>Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lifelong Vision Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lifelong Vision Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of
      dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A longitudinal, single-arm, prospective study will recruit up to 30 subjects with moderate to
      severe dry eye disease. Subjects will be &gt;18 years of age, diagnosed with moderate to severe
      dry eye (tear osmolarity &gt; 320 mOsm/L and Visual Analog Scale (VAS) score &gt; 40), willing to
      adhere to twice daily dosing (BID) and follow up visit schedule, have no history of ocular
      pathology / degeneration / allergy, not on any T-cell modulatory therapy, not have instilled
      any artificial tears within 2 hours of study visit, and not participating in any concurrent
      clinical trials. All subjects will complete an informed consent form indicating their
      voluntary participation in the study.

      Study measurements will be made at baseline (first clinic visit), 2-, 6-, and 12-weeks
      following Lifitegrast therapy and include tear osmolarity (TearLab osmolarity system), VAS
      questionnaire, slit lamp examination for fluorescein corneal staining, tear break up time
      (TBUT), and Meibomian gland dysfunction (MGD) grading . At the end of the 3-mo study visit,
      the subjects will be informed of study completion and exited from the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Actual">March 15, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: Tear osmolarity</measure>
    <time_frame>Baseline to the study completion, up to 3 months.</time_frame>
    <description>Number of participants with an improvement in Tear Osmolarity measured using the Tear Osmolarity score treated with Lifitegrast.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS</measure>
    <time_frame>VAS dry eye questionnaire, tear break up time and meibomian gland grading will be serially measured over 3 months during treatment with Lifitegrast gtts</time_frame>
    <description>Participants self scored mean average on a scale of 0: none to 10: severe of Eye Dryness, Burning/Stinging, Foreign Body Sensation, Pain, Photophobia, Itching, and Blurred Vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining Grade</measure>
    <time_frame>Baseline to the study completion, up to 3 months.</time_frame>
    <description>Percentage of cornea with cell loss/fluorescein dye uptake. The higher the percentage the higher the grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBUT</measure>
    <time_frame>Baseline to the study completion, up to 3 months.</time_frame>
    <description>Tear Film Break-Up Time; measurement of seconds it take for the tear film to start evaporating from the cornea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MGD grade</measure>
    <time_frame>Baseline to the study completion, up to 3 months.</time_frame>
    <description>Visual grading of Meibomian gland clogging.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Mild Dry Eye Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prospective 3 month study of subjects with Tear Osmolarity &gt;308 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate to Severe Dry Eye Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prospective 3 month study of subjects with Tear Osmolarity &gt;320 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifitegrast</intervention_name>
    <description>All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID</description>
    <arm_group_label>Mild Dry Eye Cohort</arm_group_label>
    <arm_group_label>Moderate to Severe Dry Eye Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tear Osmolarity &gt; 320 mOsm/L

          -  VAS eye dryness &gt; 40

          -  No other ocular pathology

          -  No contact lens wear

          -  Not currently on T cell modulator

          -  No change in therapy in last 2 months

          -  Willingness to adhere to therapy and study visits

          -  Patients qualified for prescription of lifitegrast drops

        Exclusion Criteria:

          -  Contact lens use

          -  Eye surgery in Past 6 months

          -  Use of tear supplements in past 2 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay S Pepose, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pepose Vision Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lifelong Vision Foundation</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Holland EJ, Whitley WO, Sall K, Lane SS, Raychaudhuri A, Zhang SY, Shojaei A. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials. Curr Med Res Opin. 2016 Jul 22:1-7. [Epub ahead of print]</citation>
    <PMID>27388660</PMID>
  </results_reference>
  <results_reference>
    <citation>Donnenfeld ED, Karpecki PM, Majmudar PA, Nichols KK, Raychaudhuri A, Roy M, Semba CP. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. Cornea. 2016 Jun;35(6):741-8. doi: 10.1097/ICO.0000000000000803.</citation>
    <PMID>27055211</PMID>
  </results_reference>
  <results_reference>
    <citation>Sullivan BD, Crews LA, Sönmez B, de la Paz MF, Comert E, Charoenrook V, de Araujo AL, Pepose JS, Berg MS, Kosheleff VP, Lemp MA. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea. 2012 Sep;31(9):1000-8. doi: 10.1097/ICO.0b013e318242fd60.</citation>
    <PMID>22475641</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry eye</keyword>
  <keyword>Tear osmolarity</keyword>
  <keyword>Lifitegrast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lifitegrast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

